A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

This study is the first of its kind in the United States to test a new treatment called OriCAR-017 for relapsed or refractory multiple myeloma (RR/MM), a type of blood cancer. The study will look at how safe the treatment is and how it works in the body. The treatment uses special cells called CAR-T cells to target cancer. It is called the RIGEL Study.

The study has two parts. In the first part, different doses of the treatment will be tested on up to 18 people. In the second part, up to 48 people will be treated. To join, you must be between 18 and 75 years old and have MM that has come back or not responded to other treatments. You cannot join if you are pregnant, have certain infections, or have had specific treatments recently.

• This is a multi-center study, meaning it happens in multiple locations.
• Participants will receive one intravenous (IV) infusion of the treatment.
• You must use effective birth control for 2 years after treatment.